In this study, we want to find out what effect the investigational drug Tebentafusp (IMCgp100) has on your disease. You suffer from melanoma (a type of skin cancer) that has spread or cannot be surgically removed and has worsened after standard treatments. This study includes patients with melanoma of all parts of the body except the eye.
Aim of the study
In this study, we are investigating how the investigational drug tebentafusp works and whether tebentafusp alone or in combination with pembrolizumab helps patients with advanced melanoma to live longer.
Who can take part?
Patients with melanoma (a type of skin cancer) that has spread or cannot be surgically removed and has worsened after standard treatments.
Procedure
Your participation in this study will last 2 years in the treatment phase and later 3 months in the follow-up phase. We will invite you to up to 104 appointments, but the number may vary. An appointment takes about 3 to 16 hours.
Compensation
Original study name
A randomized phase II/III study of tebentafusp as monotherapy and in combination with pembrolizumab versus investigator's choice in HLA A*02:01-positive participants with previously treated advanced melanoma (TEBE AM)
BASEC number
2023-01269
Sponsors